Teleflex has announced that it has received US FDA 510(k) clearance to market its Arrow JACC with Chlorag+ard technology and TightTrack tunneler.
Arrow JACC with Chlorag+ard technology is a long-term, tunneled, small french size antithrombogenic and antimicrobial central venous catheter designed to meet the needs of patients throughout their course of therapy or illness.
The catheter is also designed for use with high-pressure injection for diagnostic studies. The Arrow JACC with Chlorag+ard technology protects against catheter occlusion, phlebitis, and intimal hyperplasia for up to 30 days. The Arrow JACC with Chlorag+ard technology will enable caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.
“At Teleflex, we are committed to providing the right line for the right patient at the right time,” said Jay White, president of the Vascular Division. “We are proud to add the tunneled Arrow JACC to our line of vascular access products. By providing an antithromogenic and antimicrobial catheter that protects against catheter occlusion, we are offering a technology that no one else can. This is especially important in patients with end stage renal disease where vessel health and preservation is essential to provide a future dialysis vascular access.”
